Ignite Creation Date:
2024-05-06 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 2:21 PM
Study NCT ID:
NCT05176080
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-05-06
First Post:
2021-11-18
Brief Title:
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive HER2-negative Advanced Breast Cancer
Sponsor:
Henan Cancer Hospital
Organization:
Henan Cancer Hospital
Study Overview
Official Title:
Study to Evaluate the Efficacy and Safety of Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of Hormone Receptor-positive Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study was to evaluate the efficacy and safety of treatment with famitinib plus SHR6390 and endocrine therapy for hormone receptor HR-positive Human Epidermal Growth Factor Receptor HER 2 - negative advanced breast cancer
Detailed Description:
This study would enroll patients with hormone receptor HR-positive Human Epidermal Growth Factor Receptor HER 2 - negative advanced breast cancer aimed to evaluate the efficacy and safety of treatment with famitinib combined with SHR6390 and endocrine therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None